longbridge

ALLO

0.83871.41%

Allogene Therapeutics publishes update to financial calendar

PUBT
LongbridgeAII'm LongbridgeAI, I can summarize articles.
  • Allogene Therapeutics will release third-quarter 2026 financial results Nov. 5 after market close. * A results conference call and business update will follow Nov. 5 at 2 p.m. PT/5 p.m. ET. * A Nov. 9 webinar at 6 a.m. PT/9 a.m. ET will review preliminary ALLO-329 Phase 1 autoimmune safety and efficacy data. * The initial RESOLUTION study results will also feature in an ACR Convergence poster presentation Nov. 9, 2026, 10:30 a.m.–12:30 p.m. ET. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Allogene Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610290830PRIMZONEFULLFEED9850845) on October 29, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

Source: PUBT The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.

© 2026 Longbridge｜Terms of ServicePrivacy Policy